Literature DB >> 25543704

[Residual hematopoiesis is an important prognostic factor of immunosuppressive therapy in severe aplastic anemia].

Wenrui Yang1, Zhijie Wu1, Xin Zhao1, Liping Jing1, Li Zhang1, Kang Zhou1, Guangxin Peng1, Yang Li1, Lei Ye1, Yuan Li1, Jianping Li1, Huihui Fan1, Lin Song1, Fengkui Zhang1.   

Abstract

OBJECTIVE: To evaluate the prognostic value of residual bone marrow hematopoiesis in severe aplastic anemia (SAA) patients with immunosuppressive therapy (IST).
METHODS: Clinical data and hematologic responses of 38 SAA patients treated with IST regimen (antithymocyte globulin combined with cyclosporine) in our hospital were retrospectively analyzed. Correlation of pre-IST baseline reticulocyte (Ret), absolute neutrophils count (ANC), soluble transferrin receptor (sTfR) concentration, corrected TPO value and hematologic response rate were statistically analyzed and receiver operating characteristic (ROC) curve was used to estimate the value of Ret, ANC, sTfR, and corrected TPO in predicting early IST response.
RESULTS: Responders to IST had significantly higher pre-IST baseline Ret, ANC, sTfR concentration [19.9(2.7-84.4)×10⁹/L, 0.59(0.12-2.67)×10⁹/L, 0.82(0.22-1.58) mg/L] and lower corrected TPO value [142.9(31.8-1 035.0)] than non-responders [5.1(1.5-23.1)×10⁹/L, 0.20(0.04-1.33)×10⁹/L, 0.45(0.19-0.72)mg/L and 2 335.0(1 308.3-7 771.2)](P<0.05). Optimizing parameter cutoff levels obtained from ROC curve was Ret 6.75×109/L, ANC 0.30×109/L, sTfR 0.76 mg/L and corrected TPO 148.6, respectively. Combining the four parameters to predict 6 month hemotologic response showed that all the 7 patients with high Ret, ANC, sTfR and low corrected TPO, while only 1 among those 9 with low Ret, ANC, sTfR and high corrected TPO.
CONCLUSION: Such parameters evaluating residual bone marrow hematopoiesis as Ret, ANC, sTfR, corrected TPO are practical in predicting early IST response in SAA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25543704     DOI: 10.3760/cma.j.issn.0253-2727.2014.12.010

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  2 in total

1.  First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience.

Authors:  Jing Hu; Li Zhang; Xin Zhao; Xu Liu; Liping Jing; Kang Zhou; Yuan Li; Yang Li; Jianping Li; Lei Ye; Guangxin Peng; Huihui Fan; Wenrui Yang; Yang Yang; Youzhen Xiong; Lin Song; Fengkui Zhang
Journal:  Ann Hematol       Date:  2022-09-24       Impact factor: 4.030

2.  [Retreatment with immunosuppression for 23 patients with refractory or relapsed severe aplastic anemia].

Authors:  J P Li; G X Peng; L Ye; Y Li; W R Yang; Y Li; H H Fan; X Zhao; K Zhou; L P Jing; L Zhang; F K Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.